Sam Slutsky
Stock Analyst at LifeSci Capital
(4.98)
# 64
Out of 4,491 analysts
600
Total ratings
57.6%
Success rate
50.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sam Slutsky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMVT Immunovant | Maintained: Buy | $45 → $53 | $41.01 | +29.24% | 71 | Jul 9, 2026 | |
| OLMA Olema Pharmaceuticals | Maintained: Buy | $24 | $12.36 | +94.25% | 42 | Jul 2, 2026 | |
| DBVT DBV Technologies | Maintained: Buy | $46 | $16.66 | +176.19% | 12 | Jun 30, 2026 | |
| ABVX ABIVAX Société Anonyme | Maintained: Buy | $170 | $139.65 | +21.73% | 35 | Jun 30, 2026 | |
| QNCX Quince Therapeutics | Initiated Coverage: Buy | $5 | $16.92 | -70.45% | 1 | Jun 29, 2026 | |
| TCRX TScan Therapeutics | Maintained: Buy | $6 | $1.16 | +417.24% | 21 | Jun 23, 2026 | |
| DMRA Damora Therapeutics | Maintained: Buy | $45 | $28.49 | +57.95% | 6 | Jun 22, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Buy | $67 | $39.05 | +71.60% | 40 | Jun 15, 2026 | |
| SYRE Spyre Therapeutics | Maintained: Buy | $103 | $97.70 | +5.42% | 51 | Jun 15, 2026 | |
| ELVN Enliven Therapeutics | Reiterated: Buy | $60 | $51.00 | +17.65% | 37 | Jun 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $125 | $85.37 | +46.42% | 20 | May 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $2.73 | +119.78% | 20 | May 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 | $15.20 | +268.42% | 4 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.38 | - | 28 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $108 | $71.41 | +51.24% | 32 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $42 | $33.82 | +24.19% | 25 | May 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $22.66 | $9.96 | +127.52% | 7 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $222 → $225 | $151.15 | +48.86% | 23 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 | $40.53 | +35.70% | 50 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $16 | $4.56 | +251.11% | 12 | May 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.16 | - | 30 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1.16 | $1.95 | n/a | 11 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7.5 | $6.86 | n/a | 22 | Dec 27, 2022 |
Immunovant
Jul 9, 2026
Maintained: Buy
Price Target: $45 → $53
Current: $41.01
Upside: +29.24%
Olema Pharmaceuticals
Jul 2, 2026
Maintained: Buy
Price Target: $24
Current: $12.36
Upside: +94.25%
DBV Technologies
Jun 30, 2026
Maintained: Buy
Price Target: $46
Current: $16.66
Upside: +176.19%
ABIVAX Société Anonyme
Jun 30, 2026
Maintained: Buy
Price Target: $170
Current: $139.65
Upside: +21.73%
Quince Therapeutics
Jun 29, 2026
Initiated Coverage: Buy
Price Target: $5
Current: $16.92
Upside: -70.45%
TScan Therapeutics
Jun 23, 2026
Maintained: Buy
Price Target: $6
Current: $1.16
Upside: +417.24%
Damora Therapeutics
Jun 22, 2026
Maintained: Buy
Price Target: $45
Current: $28.49
Upside: +57.95%
Celldex Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $67
Current: $39.05
Upside: +71.60%
Spyre Therapeutics
Jun 15, 2026
Maintained: Buy
Price Target: $103
Current: $97.70
Upside: +5.42%
Enliven Therapeutics
Jun 11, 2026
Reiterated: Buy
Price Target: $60
Current: $51.00
Upside: +17.65%
May 23, 2026
Maintained: Buy
Price Target: $125
Current: $85.37
Upside: +46.42%
May 23, 2026
Maintained: Buy
Price Target: $6
Current: $2.73
Upside: +119.78%
May 16, 2026
Maintained: Buy
Price Target: $56
Current: $15.20
Upside: +268.42%
May 16, 2026
Maintained: Hold
Price Target: n/a
Current: $2.38
Upside: -
May 16, 2026
Maintained: Buy
Price Target: $108
Current: $71.41
Upside: +51.24%
May 16, 2026
Maintained: Buy
Price Target: $42
Current: $33.82
Upside: +24.19%
May 15, 2026
Maintained: Buy
Price Target: $22.66
Current: $9.96
Upside: +127.52%
May 9, 2026
Rated: Buy
Price Target: $222 → $225
Current: $151.15
Upside: +48.86%
May 9, 2026
Maintained: Buy
Price Target: $55
Current: $40.53
Upside: +35.70%
May 9, 2026
Maintained: Buy
Price Target: $16
Current: $4.56
Upside: +251.11%
Apr 29, 2026
Maintained: Hold
Price Target: n/a
Current: $2.16
Upside: -
Dec 14, 2023
Maintained: Hold
Price Target: $1.16
Current: $1.95
Upside: n/a
Dec 27, 2022
Rated: Buy
Price Target: $7.5
Current: $6.86
Upside: n/a